CU-2010 and CU-2020

CU-2010 and CU-2020 are synthetic compounds that act as serine protease inhibitors.[1] These were developed in 2010 to replace the use of aprotinin during and after cardiac surgery, including surgeries with cardiopulmonary bypass which cause blood loss and hemorrhagic complications.[2] CU-2010 and CU-2020 were developed to avoid many issues associated with the use of aprotinin, including the risk of an allergic reaction and infection. Since the isolation of aprotinin is expensive, a drug with a simpler synthesis was desired.[3]

  1. ^ Szabó, Gábor, et al. "The Novel Synthetic Serine Protease Inhibitor CU-2010 Dose-Dependently Reduces Postoperative Blood Loss and Improves Postischemic Recovery After Cardiac Surgery in a Canine Model." The Journal of Thoracic and Cardiovascular Surgery 139.3 (2010): 732-40. Biological Sciences.
  2. ^ "Event Brief of the Medicines Company Acquires CU-2010 and Curacyte Discovery GmbH - Final." Fair Disclosure WireAug 06 2008. ABI/INFORM Trade & Industry.
  3. ^ Mangano, Dennis T., Iulia C. Tudor, and Cynthia Dietzel. "The Risk Associated with Aprotinin in Cardiac Surgery." The New England Journal of Medicine 354.4 (2006): 353-65. ProQuest Psychology Journals.